Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지

Giniral pharmacology of CJ-50001 (rG-CSF)

CJ-50001 (rG-CSF)의 일반약리작용

  • 정성목 (제일제당(주)종합연구소) ;
  • 김영훈 (제일제당(주)종합연구소) ;
  • 신재규 (제일제당(주)종합연구소) ;
  • 최재목 (제일제당(주)종합연구소) ;
  • 고형곤 (제일제당(주)종합연구소) ;
  • 김제학 (제일제당(주)종합연구소) ;
  • 김현수 (제일제당(주)종합연구소)
  • Published : 1997.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

CJ-50001 is a recombinant granulocyte-colony stimulating factor (rG-CSF) synthesized by recombi-nant DNA technology using E. coli as an expression system. The general pharmacological properties of CJ-50001 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses are 100, 300 and 1, 0007g/kg, i.v. for mice and rats, 1, 10 and 100$\mu$g/kg, 1.v. for dogs and 1 and 10$\mu$g/ml for isolated guinea pig ileum. Intravenous administration of CJ-50001 at this dose range did not affect general behavior, central nervous system, smooth muscles, gastrointestinal system, cardiovascular and respiratory system and water and electro-lytes excretion. In summary, CJ-50001 had no harmful pharmacological erect in these studies even up to the 200-fold expected clinical dose, 2507g/man.

Keywords